Coagulation factor VIII and von Willebrand factor D'-D3 domain complex (FVIII-VWF D'D3)

Coagulation factor VIII (FVIII) is a vital glycoprotein that serves as a cofactor for factor IXa in the intrinsic pathway of the blood coagulation cascade, facilitating the activation of factor X (UniProt P00451). In the bloodstream, FVIII is primarily found in a non-covalent complex with von Willebrand factor (VWF), specifically interacting with the D' and D3 domains of VWF (UniProt P04275). This association is crucial for the stability of FVIII, as it prevents rapid clearance and degradation by plasma proteases. A deficiency in FVIII results in Hemophilia A, a condition marked by impaired hemostasis and a high risk of bleeding. Recent pharmacological advancements have utilized the VWF D'-D3 domains to create fusion proteins like Efanesoctocog alfa, which decouple FVIII from endogenous VWF to extend its therapeutic half-life (Konkle et al., 2023). These treatments allow for less frequent dosing while maintaining high levels of clotting factor activity, representing a significant advancement in the management of Hemophilia A. By engineering this specific interaction, drug developers can overcome the VWF half-life ceiling that previously limited the duration of FVIII replacement therapies (FDA Altuviiio Label).

Other names

Factor VIIIAnti-hemophilic factorFVIII-VWF complexVWF D'D3 domainBIVV001

The VWF D'-D3 domain binds to and stabilizes Coagulation factor VIII, protecting it from proteolytic degradation and clearance by the liver and kidneys, thereby extending its circulatory half-life beyond the limit imposed by endogenous VWF (FDA Altuviiio Label).